{
    "clinical_study": {
        "@rank": "109340", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double-masked, randomized, multi-center clinical study designed to evaluate the\n      safety and anatomic effects of REGN910 alone and in conjunction with intravitreal (IVT)\n      aflibercept injection in patients with DME."
        }, 
        "brief_title": "Study of REGN910 in Patients With Diabetic Macular Edema (DME)", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men or women \u226518 years of age with type 1 or 2 diabetes mellitus\n\n          2. Patients with clinically significant DME\n\n          3. Willing and able to comply with scheduled clinic visits, treatment plans, laboratory\n             tests, and other study procedures\n\n          4. Able to understand and complete study-related documents\n\n          5. Provide a signed informed consent form (ICF) prior to any study procedures\n\n        Exclusion Criteria:\n\n          1. Renal failure, dialysis, or history of renal transplant\n\n          2. Abnormal 12-lead electrocardiogram (ECG) of clinical significance at screening\n\n          3. Uncontrolled hypertension\n\n          4. Anticoagulation/anti-platelet therapy, except aspirin at doses of 325 mg or less per\n             day, low-dose warfarin or low-dose heparin\n\n          5. Major surgery (requiring general anesthesia) within 6 weeks, and other surgery within\n             4 weeks prior to screening visit\n\n          6. Pregnant or breast-feeding women\n\n        (The inclusion/ exclusion criteria provided above are not intended to contain all\n        considerations relevant to a subject's potential participation in this clinical trial)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01997164", 
            "org_study_id": "R910-DME-1301"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1", 
                "description": "Patients randomized to Group 1 will receive REGN910 on day 1/baseline (visit 2) through week 10 (visit 7)", 
                "intervention_name": "REGN910", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "Patients randomized to Group 2 will receive matching placebo on day 1/baseline (visit 2) through week 10 (visit 7)", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2"
                ], 
                "description": "Patients in both groups will receive one IVT aflibercept injection in the study eye\nPatients may receive monthly IVT aflibercept injections if certain criteria are met", 
                "intervention_name": "IVT aflibercept injection", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 22, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winter Haven", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston (2 locations)", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Peabody", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@regeneron.com", 
            "last_name": "Clinical Trials Administrator"
        }, 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint in this study is the incidence and severity of treatment-emergent adverse events (TEAEs) in patients with DME treated with REGN910 alone and in conjunction with IVT aflibercept injection", 
            "measure": "Treatment-emergent adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "baseline to week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01997164"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary outcomes of this study explore the anatomic effects of REGN910 in the retina", 
            "measure": "Anatomic effects of REGN910", 
            "safety_issue": "No", 
            "time_frame": "baseline to week 16"
        }, 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}